Is survodutide approved?

No. It is investigational. A phase 3 obesity trial was published in 2026, but there is no marketing authorization and no prescription route.

Is survodutide better than tirzepatide?

No randomized trial has compared them directly, so the honest answer is that nobody knows. They also work through different second receptors — glucagon for survodutide, GIP for tirzepatide.

What is the difference between survodutide and mazdutide?

They target the same two receptors, glucagon and GLP-1. The practical difference is regulatory: mazdutide is approved in China for chronic weight management, while survodutide is not approved anywhere.

Why is survodutide being studied in liver disease?

Glucagon-receptor activation is associated with reduced hepatic fat, which is why a glucagon/GLP-1 dual agonist was trialed in MASH with fibrosis as well as in obesity.

What Is Survodutide? Phase 3 Evidence & Comparisons (2026)

Survodutide is an investigational once-weekly glucagon/GLP-1 receptor dual agonist from Boehringer Ingelheim and Zealand Pharma. It reached a phase 3 obesity readout published in the New England Journal of Medicine in 2026 ^[1], on top of a phase 2 dose-finding trial in The Lancet Diabetes & Endocrinology ^[2] and a separate phase 2 trial in MASH with fibrosis ^[3]. It is not approved anywhere, and there is no prescription or pharmacy route to it.

The same two receptors as mazdutide

Survodutide and mazdutide target the identical receptor pair — glucagon plus GLP-1 — which makes them the clearest available comparison of how far that combination can go. The difference is regulatory, not mechanistic: mazdutide is approved in China, survodutide is not approved anywhere yet.

Against tirzepatide, the difference is mechanistic. Tirzepatide pairs GLP-1 with GIP; survodutide pairs it with glucagon. The glucagon arm is associated with increased energy expenditure and reduced liver fat rather than additional insulin secretion, which is also why survodutide has been trialed specifically in liver disease ^[3] — an indication GIP-based drugs are not primarily aimed at.

There is no head-to-head trial. “Survodutide vs tirzepatide” is a popular question with no direct answer: no randomized trial has compared them. Any percentage-versus-percentage comparison you read is assembled from separate trials with different populations, durations and endpoints, and cross-trial comparison of that kind routinely overstates differences.

Where the evidence stands

Obesity, phase 3: survodutide once weekly in adults with obesity, published in NEJM in 2026 ^[1].
Obesity, phase 2: a randomized, double-blind, placebo-controlled dose-finding trial ^[2] — the study that established the dose range carried into phase 3.
MASH with fibrosis, phase 2: a separate randomized trial ^[3], reflecting the liver-directed rationale for the glucagon arm.

For how survodutide sits alongside the other compounds in the same wave, see our pipeline roundup covering survodutide, MariTide and ecnoglutide.

There is no survodutide dose to follow

Because it is unapproved, there is no labeled dose and no dose chart. The doses that appear in the phase 2 dose-finding publication are exactly that — the range being tested, under supervision, to determine what should go forward. They are not a regimen, and material sold as “survodutide peptide” is unapproved product of unverified identity rather than a trial drug.

Frequently Asked Questions

References

1.le Roux CW, Wharton S, Startseva E, Kloer IM, Hussain SA, Unseld A, et al. Survodutide Once Weekly for the Treatment of Adults with Obesity. N Engl J Med. 2026. PMID: 42253238.
2.le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024. PMID: 38330987.
3.Sanyal AJ, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024. PMID: 38847460.

Beyond Wegovy and Zepbound: Three Pipeline GLP-1 Drugs That Could Reach Approval in 2026-2027

Survodutide (Boehringer Ingelheim/Zealand), maridebart cafraglutide (MariTide, Amgen), and ecnoglutide (Sciwind/Pfizer) are the three most-watched GLP-1 pipeline drugs that aren't being made by Lilly or Novo. We walk through the verified phase 2 and phase 3 data on each, the mechanisms, and where they fit in the post-CagriSema, post-retatrutide landscape.

11 min read

GLP-1 Pipeline Tracker: Every Next-Gen Weight-Loss Drug in Development (2026)

A living tracker of the next-generation GLP-1 and incretin drugs in development — retatrutide, CagriSema, MariTide, survodutide, amycretin, mazdutide, ecnoglutide, and the first approved oral pill orforglipron (Foundayo) — with development stage, peak reported weight loss, and a link to each fully-cited deep-dive.

7 min read

What Is Mazdutide? The Obesity Drug Approved in China, Not the US

Mazdutide is a glucagon/GLP-1 dual agonist approved in China for chronic weight management but unavailable in the US. We cover what the approval actually authorizes, how it differs from tirzepatide and retatrutide, and why an approval abroad does not make a US-sold vial legitimate.

6 min read

Mounjaro Body Odor: The Evidence and the One Red Flag

Does Mounjaro cause body odor? Tirzepatide doesn't act on sweat glands — keto breath, dehydration, and dry mouth do. The honest mechanisms and the DKA red flag.

9 min read

What is GIP? GIP Receptor Explained (And Why Mounjaro/Zepbound Activate It Alongside GLP-1)

GIP stands for glucose-dependent insulinotropic polypeptide — a 42-amino-acid gut hormone secreted by K-cells in the upper small intestine that, alongside GLP-1, accounts for the post-meal "incretin effect" (the disproportionately greater insulin response to oral glucose vs IV glucose). Tirzepatide (sold as Mounjaro for type 2 diabetes and Zepbound for obesity/OSA) is the first FDA-approved dual GIP / GLP-1 receptor agonist — the §12.1 mechanism-of-action language in both DailyMed labels states verbatim that "tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist." SURPASS-2 (Frías et al., NEJM 2021, PMID 34170647) demonstrated that dual GIP+GLP-1 agonism produces greater HbA1c reduction and greater weight loss than the single GLP-1 agonist semaglutide 1 mg head-to-head. The next-generation triple agonist retatrutide adds glucagon-receptor agonism on top of GIP+GLP-1 (Jastreboff Phase 2, NEJM 2023, PMID 37366315) — investigational, NOT FDA-approved as of 2026-05-09. This article explains what GIP is, where the receptor lives, why dual agonism beats single GLP-1 mechanism, and what the verbatim FDA labels actually say about tirzepatide's mechanism.

13 min read

Bimagrumab: The Muscle-Preserving Weight-Loss Antibody — Evidence Review

Bimagrumab is an investigational antibody that blocks ActRII to build muscle while cutting fat — the opposite of GLP-1 muscle loss. Phase 2 evidence: -20.5% fat, +3.6% lean, plus the BELIEVE bimagrumab + semaglutide trial.

9 min read

What Is Survodutide? The Glucagon/GLP-1 Dual Agonist in Phase 3

The same two receptors as mazdutide

Where the evidence stands

There is no survodutide dose to follow

Frequently Asked Questions

References

Where to get GLP-1 safely: vetted online providers

Sesame Care

Try Ageless

Sunlight

The same two receptors as mazdutide

Where the evidence stands

There is no survodutide dose to follow

Frequently Asked Questions

References

Related research

Where to get GLP-1 safely: vetted online providers

Sesame Care

Try Ageless

Sunlight